Neurology/Nervous System Diseases

Rare neurological disorders are diseases of the brain, spine, and autonomic nervous system. This section provides overviews of several of those conditions, as well news, clinical trial updates, and expert opinions form leading neurologists.

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their biological therapies.

More

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Ultragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare Brief

On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays....

Ultragenyx Sells PRV for $210M | The CheckRare Brief Ep 11

In this episode, we discuss Ultragenyx’s Priority Review Voucher that sold for $210 million, the efficacy of newborn screening on MLD, and ethical considerations needed to design and conduct...

Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10

On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It's the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. ...

FDA CDER’s Accelerating Rare Disease Cures Program

Paz Vellanki, MD, PhD, Vice President of Clinical Development at Precision for Medicine, discusses the FDA CDER’s Accelerating Rare Disease Cures (ARC) Program.    The ARC Program was launched...

New Rare Disease Center of Excellence and FDA Advances in Rare Disease | The CheckRare Brief Ep 9

This week on The CheckRare Brief, we are joined by Eugene Lee, CMI Media Group’s Group President, Specialty Communications, for an industry perspective on some of the biggest developments in rare...

Recent Videos

Current Status of Gene Therapies in Rare Neuromuscular Disorders

Current Status of Gene Therapies in Rare Neuromuscular Disorders

Drs. Beggs and Parsons discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series.

Neurology/Nervous System Diseases